Three-Year Progression-Free Survival of Metastatic Breast Cancer Treated With the Palbociclib and Letrozole Combination

被引：0
|
作者：
Karam, Imad [1 ]
Nair, Hari [2 ]
Ghani, Sofia [3 ]
Khalid, Bilal [3 ]
机构：
[1] St Lukes Hosp, PGY II Internal Med, Saginaw, MI USA
[2] St Louis Univ Hosp, PGY V Hematol & Oncol, St Louis, MI 63104 USA
[3] St Louis Univ Hosp, St Louis, MI USA
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2023年 / 30卷 / 04期
关键词：
D O I：
10.1097/MJT.0000000000001484
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：E408 / E410
页数：3
相关论文
共 50 条
  • [31] Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
    Slamon, Dennis J.
    Dieras, Veronique
    Rugo, Hope S.
    Harbeck, Nadia
    Im, Seock-Ah
    Gelmon, Karen A.
    Lipatov, Oleg N.
    Walshe, Janice M.
    Martin, Miguel
    Chavez-MacGregor, Mariana
    Bananis, Eustratios
    Gauthier, Eric
    Lu, Dongrui R.
    Kim, Sindy
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 994 - 1000
  • [32] Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
    Goldvaser, Hadar
    Ribnikar, Domen
    Fazelzad, Rouhi
    Seruga, Bostjan
    Templeton, Arnoud J.
    Ocana, Alberto
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2017, 59 : 46 - 53
  • [33] Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine
    Dogan, Izzet
    Paksoy, Nail
    Ak, Naziye
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    EUROPEAN JOURNAL OF BREAST HEALTH, 2023, 19 (02) : 128 - 133
  • [34] Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
    Goldvaser, Hadar
    Ribnikar, Domen
    Fazelzad, Rouhi
    Seruga, Bostjan
    Templeton, Arnoud J.
    Ocana, Alberto
    Amir, Eitan
    CANCER RESEARCH, 2018, 78 (04)
  • [35] Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.
    Dogan, Izzet
    Paksoy, Nail
    Ak, Naziye
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Elevated Serum Ferritin Predicts Reduced Progression-Free and Overall Survival in Trastuzumab-Treated Metastatic Breast Cancer.
    Alkhateeb, A. A.
    Connor, J.
    Leitzel, K.
    Ali, S.
    Campbell-Baird, C.
    Evans, M.
    Koestler, W.
    Fuchs, E-M
    Lipton, A.
    CANCER RESEARCH, 2011, 71
  • [37] Progression-free survival is a surrogate of survival in maintenance therapy for metastatic breast cancer: Randomized trial level analysis
    Song, E.
    Yao, H.
    Yu, Y.
    Ou, Q.
    Wang, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Progression-free survival as a surrogate endpoint in advanced breast cancer
    Miksad, Rebecca A.
    Zietemann, Vera
    Gothe, Raffaella
    Schwarzer, Ruth
    Conrads-Frank, Annette
    Schnell-Inderst, Petra
    Stollenwerk, Bjoern
    Siebert, Uwe
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2008, 24 (04) : 371 - 383
  • [39] Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
    Silva, Ariosto S.
    Kam, Yoonseok
    Khin, Zayar P.
    Minton, Susan E.
    Gillies, Robert J.
    Gatenby, Robert A.
    CANCER RESEARCH, 2012, 72 (24) : 6362 - 6370
  • [40] ELACESTRANT PROLONGS PROGRESSION-FREE SURVIVAL IN ADVANCED BREAST CANCER
    不详
    CANCER DISCOVERY, 2022, 12 (07) : 1609 - 1609
12345